Background Childhood-cancer survival is dismal in most low-income countries, but initiatives for treating paediatric cancer have substantially improved care in some of these countries. The My Child Matters programme was launched to fund projects aimed at controlling paediatric cancer in low-income and mid-income countries. We aimed to assess baseline status of paediatric cancer care in ten countries that were receiving support (Bangladesh, Egypt, Honduras, Morocco, the Philippines, Senegal, Tanzania, Ukraine, Venezuela, and Vietnam).
Introduction
Until recently, care of children with cancer has been largely neglected in low-income and mid-income countries. An estimated 160 000 new cases of cancer are diagnosed annually in children younger than 15 years of age. 1 Only about 20-30% of patients (mostly in highincome countries) are thought to be adequately diagnosed and treated. A child's probability of surviving cancer is dismal in less developed countries, and extreme discomfort is likely in the absence of palliative care. Paradoxically, most cases of childhood cancer, if diagnosed at an early stage, are highly curable if treatment is available. Furthermore, today's eff ective treatment regimens are relatively simple, inexpensive, and well established.
Paediatric oncology has improved substantially in some comparatively low-income countries, and therefore, might be improved in other countries as well. Successful initiatives have improved access to treatment in countries in central and south America, Africa, and Asia. [2] [3] [4] [5] [6] [7] [8] [9] Collectively, these initiatives are twinning partnerships that pair medical institutions in high-income countries with those in low-income and mid-income countries. These programmes can rapidly improve survival when the collaborating institutions have a long-term commit ment and when their eff orts are supported locally by alliances between public and private sectors. . The programme's purpose is to fund promising projects in paediatric-cancer control in selected low-income and mid-income countries. 14 proposed projects in ten countries 10, 11 were selected for funding. Project selection was based on fi ve main points: feasibility, potential benefi ts for the community, sustainability, possibility for serving as a model for other countries, and accountability. 10 Substantial weight was given to the accountability criterion to avoid potential mismanagement of funds. We aimed to survey the current status of paediatric oncology care in the ten countries to obtain baseline data. Here we describe the status of paediatric-cancer care and the correlates of survival in these countries.
Methods

Procedures
In the absence of more reliable data sources, the status of paediatric oncology in Bangladesh, Egypt, Honduras, Morocco, the Philippines, Senegal, Tanzania, Ukraine, Venezuela, and Vietnam was assessed by a fi eld survey. Population-based incidence estimates were used for comparison with survey data. No information from the application or selection process was used.
Field survey
Between Sept 5, 2005 , and May 26, 2006, interviews and data analysis were done by seven employees of Sanisphere (Neuilly-sur-Seine, France), a research company who specialise in public health, international aff airs, project and health-services manage ment, business, international health-care dev elop ment, and public management (webtable). The data were extensively reviewed by the My Child Matters steering committee, 10 comprising mainly medical and paediatric oncologists with extensive international experience. Survey data are shown in tables 1 and 2.
First, each country was visited for 3 weeks between Sept 5, 2005, and May 26, 2006, by three Sanisphere employees (webtable). The survey comprised qualitative face-to-face interviews with oncologists of paediatric and adult cancers, family doctors, nurses, pharmacists, hospital managers, cancer-registry employees, government health offi cials, embassy employees, and representatives of international and local non-governmental and religious agencies (table 1) . No standard forms were used, but a set of basic questions were asked in all interviews, including the estimated number of children at each step of the paediatric cancer-care chain, the number and description of paediatric-oncology units, the number of beds available for paediatric oncology, and the number of paediatric oncologists and nurses. The main purpose of the survey was to ascertain the availability of national paediatric-cancer programmes, dedicated paediatric-cancer hospital units, diagnostic resources, regular supplies of anti neoplastic and antibiotic drugs, radio therapy facilities, treatment guidelines or protocols, palliative-care programmes, parent support or advocacy organisa tions, paediatric oncology or haematology societies, and international partners. Diagnostic resources were classifi ed by the interviewers as poor, limited, or adequate on the basis of timely access to the minimum necessary diagnostic procedures. Poor access was defi ned as nonexistent or unavailable access for most children with cancer; limited access was defi ned as inconsistent access or a long wait for results; and adequate access was defi ned as basic, timely diagnostic procedures available for most children. Availability of medications, blood products, and radiotherapy was deemed poor if they were unavailable to all or most children with cancer; limited if their availability was irregular; and adequate if they were available for most children in a timely manner.
The minimum requirement for diagnosis of solid tumours was histological assessment of haematoxylin and eosin-stained tumour sections. For diagnosis of leukaemia, assessment of a bone-marrow smear with WrightGiemsa and myeloperoxidase staining was needed. Staging of solid tumours had to have been done by ultrasonography and CT. Minimum diagnostic resources for all cancers included the necessary medical expertise to interpret the diagnostic studies. The con sistent availability (ie, accessibility to all or most patients) of pain control, psychosocial support, chemotherapy drugs, blood products, and antimicrobial drugs overall was classifi ed as adequate or inadequate by the interviewers.
Estimation of paediatric-cancer incidence
The interviewers estimated the number of patients seen by each country's medical services on the basis of interview data from health-care providers and hospital-based registries. To assess the survey data, we used incidence data for each country obtained from existing, internationally reviewed, population-based cancer regist ries within that country or region for various time periods between 1982 and 2002. 1, [12] [13] [14] [15] Incidence data for Egypt, 14 the Philippines, 14 and Vietnam 12, 13, 15 were obtained from regional population-based cancer registries. Incidence data for the remaining countries were obtained from cancer registries in neighbouring countries. The assumptions underlying the choice of surrogate population-based registries have been described else where. 13 Briefl y, surrogate countries were chosen on the basis of location adjacent to the country of interest, availability of population-based cancer data, and similarity to the reference population.
Postulated survival of paediatric cancer
Postulated survival in each country was derived from all available interview data. It was not possible to meet the criteria for standard statistical methodology because of great variation in the data sources and settings, and the scarcity of population-based or hospital-based registries. When consistent survival estimates were obtained from diff erent sources in a country, the mean was calculated. When the estimates were inconsistent, more weight was given to sources closest to the clinical management of childhood cancer, unless their estimates diff ered substantially from all others. For example, in Morocco, 750-800 patients were seen annually (table 2) , and all but 20 patients were treated in hospitals with cancer registries. We therefore based the postulated survival on the survival information derived from these cancer registries (about 300-350 survivors) together with the about 1000 new cases per year estimated from incidence data (table 3) , arriving at about 30% survival. Because of the absence of systematic follow-up, postulated survival represents only short-term survival and might be overestimated.
Demographic, health, and socioeconomic data
For comparison and analytical purposes, we obtained data for each country from various sources. Government annual health-care expenditure per capita and number of 18 and mortality data in patients aged under 5 years and per capita gross national income (GNI) in 2006 were obtained from the United Nations Children's Fund (UNICEF). 19 2005 human development and human poverty indices were obtained from the UN Development Programme (UNDP). 20 The human development index, a composite, normalised measure of life expectancy, literacy, education, standard of living, and gross domestic product (GDP) per capita, is a standard measure of well being, especially child welfare, for countries worldwide. The human poverty index is a composite index that measures deprivation in three basic dimensions: a long and healthy life, knowledge, and standard of living. The statistical procedures used to derive these indices have been described elsewhere. and reports on childhood-cancer survival were obtained from European 23 and US 24 cancer registry data. We studied the correlation of these parameters, including incidence of paediatric cancer, survival, and access to care, with data obtained from the fi eld surveys.
Statistical analysis
The correlation between postulated childhood-cancer survival in the ten countries overall and demographic, health, and socioeconomic data was calculated as the Pearson's correlation coeffi cient (r) and Pearson's coeffi cient (r²) by use of SAS (version 9.1). Logistic regression models were used to ascertain the correlation between combinations of predictive variables and postulated cancer survival. A corresponding probability value of 0·05 or less was deemed to show a signifi cant correlation. Because the incidence of paediatric cancer is expected to increase as mortality from diseases of poverty decreases in most of the ten surveyed countries, we also estimated the future annual incidence of paediatric cancer in these countries by assuming that it will equal current European incidence (140 cases per million) 17 by 2025.
Role of the funding source
The sponsors of the My Child Matters programme (Sanofi -Aventis and UICC) had no role in the study concept, design, or in the collection, analysis, or interpretation of the data. The sponsors contracted Sanisphere to undertake a fi eld study to ascertain baseline data on the countries chosen to receive My Child Matters grants. After Sanisphere employees presented the data to the My Child Matters steering committee, the authors analysed the data further and prepared the report. The steering committee members did not receive honoraria from UICC or Sanofi -Aventis for this activity. The authors were responsible for the concept, design, and the data analysis and preparation of the report. All authors had access to all the data in the study. RCR had the fi nal decision to submit for publication. Tanzania had no formally trained paediatric haematologists or oncologists. Paediatric cancer was managed in the single Tanzanian paediatric-cancer unit (public) by a clinician assisted by radiation oncologists; in the other hospitals, public or private, paediatric cancer was mainly managed by paediatricians or family doctors. By contrast, Ukraine had 250 paediatric haematologists or oncologists (one special ist for every four incident cases). These ratios were 1:10 in the Philippines, 1:23 in Egypt, and 1:28 in Venezuela, which are considered adequate. 25 The remaining coun tries had ratios of 1:50 to 1:750, which are clearly inade quate for proper cancer care. Data from WHO suggested a median of 0·55 physicians of any type per 1000 pop ulation in the surveyed countries (range 0·06 in Senegal to 2·95 in Ukraine) and a median of 0·56 nurses (range 0·14 in Bangladesh to 7·62 in Ukraine; table 4).
Results
Availability of diagnostic testing was poor or limited in eight of the ten countries, in which there was typically no expertise in the histological diagnosis of paediatric cancers, no consistent supply of immunohistochemical reagents, long delays for pathology reports (as long as 1 month in Tanzania), or limited access to modern imaging or to other diagnostic technologies (or both). Modern diagnostic technology and access to it were adequate only in Ukraine and Venezuela. In Egypt, Honduras, Morocco, and the Philip pines, diagnostic resources were available, but were inaccessible to most patients living outside of the countries' largest cities.
Overall management of paediatric cancer and availability of medication, radiotherapy, and blood products was deemed poor or limited in seven countries. Only in Egypt, Ukraine, and Venezuela did most children diagnosed with cancer have access to anticancer drugs, antibiotics, blood products, and radiotherapy. Uniform treatment guidelines were absent in all countries except Ukraine, which uses national guidelines based on international protocols.
Postulated 5-year survival (table 2) was 5% to 10% in Bangladesh, the Philippines, Senegal, Tanzania, and Vietnam; 30% in Morocco; and 40% to 60% in Egypt, Honduras, Ukraine, and Venezuela. Demographic, economic, and health-care indicators relevant to population health also varied widely between all the countries (table 4). Several of these indicators were Total population (×1000) 16 Physicians per 1000 population* 18 Nurses per 1000 population 18 Mortality in patients aged <5 years (per 1000) 19 Per capita GDP (US$) 22 Total per capita health-care expenditure (US$) 18 Per capita government healthcare expenditure (US$) 18 Human development index 20 Human poverty index 20 Bangladesh 144 ) . Surprisingly, the human development index (r²=0·398; p=0·050) and human poverty index (r²=0·351; p=0·093), which are commonly used to rank countries' economic performance, were also not correlated with postulated survival. We also studied the correlation between the fi ndings of the fi eld survey (table 1) and postulated 5-year survival. As expected, indicators suggestive of the availability of paediatriccancer services were correlated with postulated survival (table 6) .
We then compared the correlation of annual government health-care expenditure per capita with the estimated survival rates of children with cancer in all ten countries, 18 European countries, 23 and the USA 24 (fi gure). The correlation was strongest at the low end of the expenditure range (r²=0·882; p<0·0001 for expenditures <US$100) and weakest at the high end (r²=0·10; p=0·27 for expenditures >US$1000). 
Diagnostics and therapeutics
Availability of diagnostic services 0·95 0·90 <0·0001
Availability of medications, radiotherapy, blood products 0·89 0·80 0·0005
Uniform treatment guidelines 0·88 0·78 0·0007
*Aged under 15 years. 
Discussion
Data from our fi eld survey have shown that the postulated overall survival of children with cancer is dismal in Bangladesh, the Philippines, Senegal, Tanzania, and Vietnam, but is much better in Ukraine and Venezuela. Egypt, Honduras, and Morocco rank between these two groups. Postulated survival in the ten countries was signifi cantly correlated with several socioeconomic and health-related indices established by international agencies, including total annual health-care expenditure, per capita GDP, per capita GNI, and the number of physicians and nurses per 1000 population; however, only annual govern ment health-care spending per capita was independently correlated. Future research should focus on specifi c characteristics of public-health infrastructure represented by these expenditures and how they are associated with childhood-cancer survival.
Importantly, we noted that per capita annual healthcare expenditure was signifi cantly associated with childhood-cancer survival only in the lowest expenditure range. Not surprisingly, survival data were most favourable in countries where children are promptly referred to well-equipped tertiary-care centres. However, about 25-30% of patients are not successfully treated, even with optimum treatment. Therefore, once access to early diagnosis and adequate care (with the requisite hospital infrastructure) are available, additional investment of public-health resources has a smaller benefi cial eff ect on survival. Because childhood cancer has a low overall incidence and most patients can be managed without complex infrastructure or procedures, a relatively small investment by governments or private sectors in conjunction with local organisations might make a large diff erence in survival in low-income and mid-income countries.
The absence of correlation between mortality in patients aged under 5 years and postulated survival was not surprising; this disparity has been seen in many low-income and mid-income countries. [26] [27] [28] We made this comparison because global health agencies deem mortality in patients aged under 5 years an important indicator of children's health. However, paediatric cancer is not a factor in mortality in this age group because of its relative rarity and its underdiagnosis in many countries. For example, even if all childhood cancer in Senegal were cured, Senegal's mortality in patients aged under 5 years would diminish only negligibly. Therefore, assistance or advocacy, or both, for treatment of paediatric cancer is unlikely to come from agencies that focus on child health in general. The relatively low mortality in this age group in some surveyed countries with poor postulated cancer survival suggests they have adequate basic public-health measures, but the economic, professional, technological, and infrastructure resources needed for eff ective management of childhood cancer remain unavailable; abandonment of therapy is also likely to be a factor. 29, 30 Our study was substantially aff ected by a scarcity of population-based or even hospital-based cancer registries in most of the countries surveyed. Egypt, the Philippines, and Vietnam have regional population-based cancer registries that provide data for international comparative studies. 12, 14 Ukraine has an established national pop ulation-based cancer registry, although its data has not been reviewed internationally. The estimated incidence of childhood cancer in Ukraine (based on reliable data from surrounding countries) is 135 per million person-years, 13 and our survey data yielded a postulated overall survival of about 50%. These estimates diff er slightly from those reported by the Ukrainian national pop ulation-based registry 31 (incidence 120 per million person-years, and mortality 46 per million person-years in children aged under 15 years). However, under the crude assumption that mortality=incidence ×(1-survival), the Ukraine national population-based registry would predict overall survival as 62%. Because there is an estimated 20% proportion of under-reporting to the Ukraine national population-based registry, the survey data are not inconsistent with this survival prediction.
Our study had some limitations. We used incidence data estimated from reliable (although not necessarily representative) sources in or outside of the ten countries. Use of incidence data from surrogate countries is not an ideal method of estimation, but yielded the best available approximation (equally likely to deviate from the true incidence in either direction). The probability of 5-year survival was estimated by inter viewing clinicians who directly cared for children with cancer, but who do not usually provide long-term follow-up. We should also acknowledge that low-income and mid-income countries can undergo rapid changes in health, demographic, and economic measures, especially during war or natural disaster, although to our knowledge there were no substantial changes in the surveyed countries during the study. Despite the possibility that our data are incomplete and biased, they provide the only currently available means of defi ning a baseline for use in assessing future progress.
Improvement of paediatric-cancer survival in lowincome and mid-income countries might need alliances that combine government, public and private sectors, and medical societies. 7 Chile provides a remarkable example of what can be accomplished. Paediatriconcology care in Chile has improved substantially over the past two decades through a strong alliance between the public and private sectors, and through the oversight of the Chilean Ministry of Health. 32, 33 Honduras and Morocco, which have relatively high mortality in children aged under 5 years, have also made substantial progress in the past few years, including expansion of access to care, improvement of supportive care and diagnostic capabilities, decrease of therapy abandonment and late diagnosis, and establishment of uniform treatment guidelines adapted to local resources. This progress has been helped by use of twinning programmes with St Jude Children's Research Hospital and by Morocco's participation in the French-African Paediatric Oncology Group. 5, 29, 34, 35 The Honduran and Moroccan institutions have also created local nongovernmental organisations that provide psychosocial and fi nancial support to patients' families. Such organisations also work to increase awareness that paediatric cancer is curable, enlist community leaders, and campaign for national paediatric-cancer programmes. Most importantly, their fundraising activities sustain these programmes.
Twinning programmes enable rapid and relatively inexpensive improvement of survival of childhood cancer even in countries without optimum medical infrastructure and public-health funds. In countries where mortality in children aged under 5 years is relatively low, but where overall childhood-cancer survival is very poor-such as the Philippines, Vietnam, and many others-eff ective twinning programmes might prompt rapid progress. Paediatric-oncology units implemented and maintained through such pro grammes also promote national, regional, and international alliances, as exemplifi ed in Honduras, Morocco, and other countries. As countries develop economically and can increase their investment in health care, the benefi cial eff ect of twinning programmes will probably decrease.
A major challenge for the My Child Matters programme is the long-term sustainability of funded projects in paediatric oncology. Sustainability is an especially crucial consideration in countries such as Tanzania, Senegal, Vietnam, and the Philippines, which have many competing needs and few resources. One or more twinning sites in these countries, once established, might rapidly incor porate modern paediatric-cancer care. These centres could then serve as training sites for additional health-care providers and as community education resources. Eventually, regional collaboration and the participation of government and private agencies could expand access to a national level.
In summary, detailed surveys can provide useful data for baseline assessment of the status of paediatric oncology, but cannot substitute for national cancer registration. We suggest that paediatric-oncology registration in low-income and mid-income countries begin with the setting up of hospital-based registries,
